Ozempic, Monjaro, Zepbound - The Arthritis and Autoimmune Disease SECRET Nobody Is Talking About

What is the power of GLP-1 medications in managing arthritis and autoimmune diseases, without the need for dramatic weight loss?

 In this episode, Dr. Diana Girnita, a double board-certified rheumatologist and founder of Rheumatologist OnCall, explores how microdosing Ozempic, Wegovy, Mounjaro, Wegovy and Zepbound can revolutionize treatment plans for those battling persistent inflammation, pain, and flare-ups.

While everyone is talking about these medications, few discuss their potential for arthritis and autoimmune conditions. 

Dr. Girnita delves into the research, explaining the differences between semaglutide and tirzepatide, the five mechanisms that combat inflammation independently of weight loss, and the latest insights from 2025 data on conditions like rheumatoid arthritis, psoriatic arthritis, lupus, Sjogren's, osteoarthritis, and gout.

You'll discover:

• How metabolic inflammation affects biologics and the importance of addressing fat tissue’s inflammatory signals.
• The groundbreaking 2025 research showing GLP-1 drugs' ability to reduce disease activity and pain without weight loss.
• The potential of microdosing these medications for patients with uncontrolled autoimmune diseases.
• The benefits of combining metabolic modulation with conventional therapies to reduce flare-ups and cardiovascular risk.
• How these findings are reshaping rheumatology practice and future treatment options.

Topics Covered:

• Differences between Ozempic, Wegovy, Mounjaro, and Zepbound.
• The role of fat cells in fueling arthritis.
• Five mechanisms GLP-1 medications use to fight inflammation.
• The concept and effectiveness of GLP-1 microdosing for arthritis.
• Insights from 2025 research on various autoimmune conditions and cardiovascular risk.
• How GLP-1 complements DMARDs and biologics without replacing them.

This episode is ideal for those tired of hitting a plateau, exhausted by constant flare-ups, or healthcare professionals eager to integrate cutting-edge science into patient care. Ignoring this emerging science risks leaving persistent inflammation untreated—missed opportunities that could transform your health.

Join Dr. Girnita in exploring how small changes in medication strategy, driven by the latest science, can unlock significant improvements—beyond weight loss—offering hope, control, and relief from autoimmune chaos.

Are you ready to rethink what’s possible in your autoimmune journey? This isn’t just another episode—it's a paradigm shift in managing inflammation at its core.

Transcript

What if I told you the answer to your ongoing arthritis flares isn't a higher dose of your biologic, isn't switching medications for the third time — it might something that everyone is talking about?

Ozempic. Wegovy. Mounjaro. Zepbound. You know these names. You've probably seen them in your news feed, on talk shows, maybe even in your conversations with your friends. 

But here's what the conversation is completely missing—and what I'm seeing every single week in my rheumatology practice: these medications, even at very small doses, may be among the most powerful tools we have right now for bringing arthritis and autoimmune diseases under control.

I'm Dr. Diana Girnita — double board-certified rheumatologist, over 20 years of clinical experience, founder of Rheumatologist OnCall® — and for the past 3 years, I have witnessed changes that are truly remarkable in my patients using these drugs!

 I will tell you exactly what is happening inside your body when arthritis, autoimmune diseases, and weight intersect.

Why the standard approach of just adjusting your DMARD or biologic is sometimes missing a critical piece,

What the brand new science says about these medications, and we will talk about disease by disease, and why even very small doses of these medications can change everything in your treatment plan.

Let's get into it.

SEGMENT 1 — Let Me Introduce the Family: Ozempic, Wegovy, Mounjaro, Zepbound

Let me start by clearing up the confusion — because every week in my office, patients are mixing these names up, and it matters.

There are two molecules we're talking about. 

The first is semaglutide — that's the ingredient inside both Ozempic and Wegovy. 

Ozempic is the lower-dose version, approved for type 2 diabetes. 

Wegovy is the higher-dose version, approved for obesity and weight management. Same molecule. Different doses. Different FDA labels.

The second is tirzepatide — that's the ingredient inside both Mounjaro and Zepbound. 

Mounjaro is diabetes. Zepbound is obesity. Again — same molecule, two brand names.

Now here's the clinically important difference between the two families. 

Semaglutide activates one receptor — GLP-1. 

Tirzepatide activates two receptors simultaneously — GLP-1 and GIP. 

That dual action makes tirzepatide more powerful for weight loss on average — and a 2025 meta-analysis showed it reduces our key inflammation markers, hsCRP and IL-6, more potently than placebo across every tested dose. We're talking a roughly 33% reduction in CRP and 18% reduction in IL-6.

So when I say "GLP-1 medications" — I mean this entire family. But semaglutide and tirzepatide are the ones generating the most excitement right now. And for good reason.

"But why would a metabolic medication have any effect on inflamed joints? The answer starts with something that happens inside your fat cells — and once you understand this, your entire picture of arthritis changes..."

SEGMENT 2 — Your Fat Cells Are Running an Inflammation Factory

Obesity and arthritis are not two separate problems. They share the same root — and that root is chronic inflammation coming from your own fat tissue.

Here is something most patients have never been told. 

And honestly — something many doctors don't fully connect either.

If you have arthritis and you carry extra weight, those two things are not independent. 

Your fat cells — your adipose tissue — are not sitting quietly in storage. They are biologically active. They are producing a constant stream of inflammatory chemicals called cytokines. Specifically: IL-6, TNF-alpha, IL-17, and IL-1.

Here's why that matters.

Those are the exact same molecules that drive rheumatoid arthritis, psoriatic arthritis, and lupus. 

They are the same molecules that expensive biologic medications are designed to block.

So picture this: you are on a biologic that is trying to quiet your inflammation. And at the same time, your fat tissue is continuously pumping those exact same inflammatory molecules back into your bloodstream. Around the clock. Every day.

This is why, in many patients with RA and psoriatic arthritis, biologics work only partially. It's not that the biologic is wrong. 

It's that the metabolic inflammation is undercutting it. 

Obesity has been shown in multiple studies to reduce the effectiveness of DMARDs and biologics — and in some patients, it is literally blunting the drug response without anyone realizing it.

And it does not stop at joints. 

This chronic inflammation travels to your heart, your blood vessels, your kidneys. Patients with RA and lupus already carry a significantly elevated cardiovascular risk just from their disease. Add metabolic inflammation on top of that — and you have a compounding problem that we need to address at the root.

That is the missing piece. 

Not a higher biologic dose. 

Treating the metabolic inflammation at the source.

"So what do Ozempic and Mounjaro actually do about this? 

Because it turns out they work on inflammation through five completely different pathways — and some of them work even without losing a single pound..."

SEGMENT 3 — Five Ways These Medications Fight Your Arthritis (And One Will Surprise You)

GLP- 1 and dual GLP- 1 GIP medications attack inflammation through at least five separate mechanisms — and one of them is completely independent of weight loss.

This is the part most doctors are not yet explaining to their patients. 

So I want to be very specific.

Number one — cutting the fat-driven inflammatory supply. 

When you lose even 5 to 10% of your body weight on Ozempic, Mounjaro, or Zepbound, you dramatically reduce the IL-6, TNF-alpha, and IL-1 beta output from your fat tissue.

Less metabolic inflammation fuel — and your biologic or DMARD immediately works better.

Number two — direct anti-inflammatory action, independent of weight. 

This is the one that is changing the entire field. 

Research published in the Journal of Clinical Rheumatology in 2024 confirmed that GLP-1 analogs inhibit the NF-kB pathway — one of the master switches of inflammation .

This was demonstrated directly in RA and psoriasis cell models. 

The drug is turning down inflammation at the molecular level, even before you lose a gram of weight. This means even a very small dose — what we call microdosing — can have meaningful anti-inflammatory effects in arthritis patients who are not obese.

Number three — restoring gut health.

There is an established gut-joint connection in autoimmune disease. A disrupted gut microbiome generates immune activation that reaches your joints. 

GLP-1 medications improve gut microbiome diversity and reduce gut permeability. 

Research published in Science in 2025 even identified a specific gut-joint axis — via bile acid metabolism — through which GLP-1 medications directly protect joint cartilage and reduce the osteoarthritis, or the wear and tear arthritis.

Number four — reversing insulin resistance. 

Many patients with RA, psoriatic arthritis, and lupus have insulin resistance that they are completely unaware of. 

Insulin resistance feeds the chronic inflammation cycle. 

Both semaglutide and especially tirzepatide, with its dual action, break that cycle powerfully.

Number five — reducing oxidative stress and protecting cartilage. 

Oxidative stress accelerates cartilage destruction — especially in osteoarthritis. GLP-1 medications reduce body-wide oxidative stress markers, which may help protect joint structure beyond just reducing pain.

The message here is layered. 

These are not just weight loss drugs. 

They are metabolic modulators with direct anti-inflammatory properties — and the evidence now covers five distinct pathways.

"And here is where the clinical picture gets really exciting. Because what the 2025 research is now showing us — disease by disease — is something even I didn't expect to see this quickly..."

SEGMENT 4 — What the 2025 Research Shows, Disease by Disease

The data presented at ACR Convergence 2025 and in peer-reviewed journals this last year is rewriting the treatment conversation for RA, psoriatic arthritis, osteoarthritis, gout, and lupus.

Rheumatoid Arthritis:

Let me start with a study that every RA patient needs to hear about.

It was published in the last ACR meeting. Researchers from UCLA followed 173 RA patients who started semaglutide or tirzepatide between 2018 and 2024, and compared them against 42 RA patients who were prescribed a GLP-1 but chose not to take it. After one year, the patients who took the medication had significantly lower RA disease activity scores, a meaningful drop in pain — while the control group's pain actually got worse — CRP and ESR fell, cholesterol improved, and weight dropped by an average of 4.4 kilograms versus 1.2 in controls.          All statistically significant.

Another study of over 12,000 RA patients found that people using semaglutide users had a significantlyjoint stiffness, pain, swelling, and synovitis at 30 days, 3 months, and one full year compared to those who did not use this drug, and the researchers attributed this partly to direct immune modulation, reduced inflammation and not just weight loss.

The critical clinical take-away: GLP-1 does not replace your DMARD or biologic. 

But it can make your existing treatment work significantly better — and for some patients, it creates the possibility of actually reducing their drug burden over time rather than escalating it.

Psoriatic Arthritis:

Let me tell you about Daniel, one of my patients.  He is a real patient — 33 years old, 280 pounds, ten years of psoriasis and psoriatic arthritis, and failed multiple medications. 

I had him on a weight-based biologic infusion — and even that wasn't giving him adequate control.

About 3 years ago, I started him on GLP-1 medication.

Within months, his skin began to clear. 

Joint pain came down. 

Morning stiffness improved. 

By the six-month mark his disease was better controlled than it had been in a decade — not because we replaced his biologic, but because reducing the metabolic inflammation made the biologic work the way it was designed to.

The 2025 ACR congress included studies  on PsA, which confirms exactly this. 

A study of 48 PsA patients on GLP-1 therapy showed significant weight loss but also a great improvement in the joint pain, lower disease activity, and decreased markerskers of inflammation like CRP.

But not only that… another study led by Harvard researchers showed that people using GLP-1 drugs had a significantly reduced risk of developing new psoriatic arthritis compared to patients on other diabetes medications.

And then, something very important! These drugs, GLP-1 medications if they are used in patients with PsA, they seems to reduce the risk of CV events, which means fewer heart attacks, fewer strokes, and fewer deaths due to heart disease.  

Psoriatic arthritis patients already carry elevated cardiovascular risk… and this study showed the use of GLP -1 saves lives!

This is not just about joint pain. This is about protecting your heart.

Osteoarthritis:

A study published in New England Journal of Medicine in 2024, which enrolled 400 patients with knee OA and obesity at 61 sites across 11 countries, showed that patients on semaglutide lost about 14% of body weight versus just 3% on placebo. 

But the pain reduction went far beyond what weight loss alone could explain — their knee pain score dropped 41 points versus just 27 on placebo. 

Physical function improved significantly. 

This is a landmark trial that is changing how orthopedic surgeons and rheumatologists think about OA management before resorting to surgical options.

Gout — The Honest Picture:

I have to give you the full, honest story here because gout is nuanced. 

When patients first start GLP-1 therapy and lose weight rapidly, uric acid can temporarily spike — because rapid fat breakdown releases purines into the bloodstream that convert to uric acid. This can trigger an early gout flare.

I have seen it, the research reflects it, and it is real.

But here's what matters: this is a short-term effect. 

Long-term data shows that once weight stabilizes, GLP-1 medications appear to lower uric acid and reduce flare frequency. 

The same phenomenon happens after bariatric surgery. 

Managing this transition requires a rheumatologist — not a weight loss clinic — because you need someone who understands both conditions simultaneously and can protect you through that early window.

Lupus, Sjögren's, Ankylosing Spondylitis:

The evidence here is earlier but growing fast. There are some small studies in lupus patients on GLP-1 therapy that showed less flare-ups, or that GLP-1 medications may slow progression to kidney disease in patients with lupus nephritis. 

There are also studies showing that GLP-1 use was associated with a significantly reduced risk of developing new autoimmune diseases overall. 

So far we dont have specific studies for patients with Sjogren’s and AS.

"The science is accelerating. But here is the conversation I want to have that nobody else is having yet — because it changes who this is for..."

SEGMENT 5 — The Microdosing Conversation: Why Less Might Be Exactly Enough

You don't have to need major weight loss to benefit. Microdosing GLP-1 medications — small, targeted doses — may be the key for arthritis patients who are already on treatment but not fully controlled.

Here is the part of this conversation that I find most exciting — and most underused in rheumatology right now.

When most people think about Ozempic or Zepbound, they picture significant weight loss. 

Big doses. 

Major metabolic transformation. 

And that's valid for many patients. 

But here is what I am seeing in my clinic that I think is genuinely underappreciated: even very small doses — what clinicians are calling microdoses — are producing meaningful clinical improvements in arthritis patients.

What does that mean practically? 

Instead of pushing to the full therapeutic dose designed for maximum weight loss, some patients are started at a very low dose — just enough to begin modulating the metabolic and inflammatory pathways, without significant appetite suppression or major weight change.

And the results can be remarkable.

I had a patient from Arizona — maximized on her RA treatment, on both a DMARD and a biologic, still having multiple flares per month, exhausted, in pain.

Four months after starting a GLP-1 microdose, her flares dropped from multiple per month to one per month.

 Her energy improved significantly. 

We are now actually tapering down her medication — not escalating it.

Why does this work? 

Because, as we just talked about, the anti-inflammatory effects of these medications operate through the pathways that operate independently of weight loss. 

You don't need to lose 15% of your body weight to get the anti-inflammatory benefit. 

Even a gentle, consistent metabolic signal — delivered at low dose — can reduce the fat-driven cytokine output and calm the immune activation that is undermining your DMARD or biologic.

This approach is especially relevant for patients who are not significantly overweight but have metabolic inflammation — patients with insulin resistance, prediabetes, or elevated CRP who are struggling to achieve full disease control despite adequate drug doses.

The key message I want you to take home: before we escalate your arthritis medication — before we switch to a more aggressive biologic, before we increase your DMARD dose — the question I now ask in every patient visit is: have we addressed the metabolic inflammation? Because if we haven't, we are managing the fire while leaving the fuel on.

Let me bring this together.

Ozempic, Wegovy — semaglutide. Mounjaro, Zepbound — tirzepatide. 

These medications are not replacing your DMARDs or your biologics. 

THIS IS IMPORTANT!

But they are emerging as one of the most powerful complements to your arthritis treatment that we have right now — because they address the metabolic inflammation that conventional rheumatology treatments don't touch.

The research from big academic centers like UCLA and Harvard— it all points in the same direction. 

Less joint pain. Fewer flares. Lower cardiovascular risk. Better response to existing medications. 

And for a carefully selected group of patients, even microdoses can produce real, measurable, life-changing results.

If you have arthritis and you feel like you've been stuck — your medications are doing something but not enough, your flares keep coming, your fatigue isn't going away — there may be a metabolic piece of your puzzle that nobody has addressed yet.